NEW YORK, March 11, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced it has priced an underwritten sale of 2,702,809 shares of its common stock at $6.71 per share, the closing price on March 11, 2014, to JP Morgan Asset Management's Global Healthcare Fund. Gross proceeds from the sale are expected to be approximately $18.1 million. TG Therapeutics intends to use the proceeds from the offering to fund the clinical development of TG-1101 and TGR-1202 and other general corporate purposes. The offering is expected to close on or about March 17, 2014, subject to customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.
